TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8233298
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with carboplatin (400 mg/m2 day 1) and 5-fluorouracil (1 g/m2 days 1-5) followed by locoregional treatment (LRT)
Study: 8233298
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment (LRT) alone
Study: 2891370
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine orally alone
Study: 2891370
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine orally with antacid
Study: 2891370
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine orally with a standard breakfast
Study: 28631456
Drug: Adenosine group
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine group (20 mL of bupivacaine hydrochloride 0.375% + 12 mg adenosine in 2 mL of saline 0.9%)
Study: 28631456
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group (20 mL of bupivacaine hydrochloride 0.375% + 500 mg magnesium sulphate in 2 mL saline 0.9%)
Study: 28631456
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mL of bupivacaine hydrochloride 0.375% + 2 mL saline 0.9%)
Study: 27236075
Drug: No-treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment condition (n = 13)
Study: 26817717
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg FA/d
Study: 20620713
Drug: Carotid Augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid Augmentation Index (cAI(x))
Study: 16614274
Drug: Nicorandil added
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil added to existing antianginal treatment
Study: 10649211
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug (placebo-controlled)
Study: 8402740
Drug: diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 60 mg tid
Study: 8402740
Drug: diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem SR 120 mg bid
Study: 3079940
Drug: PY 108-068
Normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY 108-068 (75 mg/day)
Study: 3079940
Drug: PY 108-068
Normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY 108-068 (150 mg/day)
Study: 29111391
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with scaling and root planing (SRP)
Study: 29111391
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with SRP
Study: 18180637
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% lidocaine
Study: 18180637
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% amitriptyline
Study: 12526955
Drug: L-NMMA (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (12.5, 25, and 50 microg/kg/min for Low; 25, 50, and 100 microg/kg/min for High)
Study: 12526955
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusions only)
Study: 20560730
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily
Study: 8730416
Drug: Calcium dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dialysate (CaD) of 1.75 mmol/l
Study: 8730416
Drug: Calcium dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dialysate (CaD) of 1.25 mmol/l
Study: 1407617
Drug: Antibiotic pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic pretreatment of heart valve prostheses
Study: 3930246
Drug: Aspirin 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 0.45 mg kg‐1 day‐1
Study: 24612027
Drug: Superficial dermabrasion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial dermabrasion (16 weekly sessions)
Study: 24612027
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin cream (0.05% daily)
Study: 19854610
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DAB) 110 mg
Study: 19854610
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DAB) 150 mg
Study: 19854610
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DAB) 220 mg
Study: 17913961
Drug: TNF-alpha -308
Normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha -308 G/A allele frequencies in women with pregnancy complications (cases)
Study: 17913961
Drug: TNF-alpha -308
Normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha -308 G/A allele frequencies in women without pregnancy complications (controls)
Study: 17913961
Drug: TNF-alpha -308
Normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha -308 G/A genotype distributions in women with pregnancy complications (cases)
Study: 17913961
Drug: TNF-alpha -308
Normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha -308 G/A genotype distributions in women without pregnancy complications (controls)
Study: 17913961
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of TNF-alpha -308 G/A genotype distributions between cases and controls
Study: 17913961
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of TNF-alpha -308 G/A allele frequencies between cases and controls
Study: 15911462
Drug: Zinc as
Normalized name: Zinc aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc as an adjuvant to malaria therapy
Study: 12126383
Drug: Refrigerant spray
Normalized name: Refrigerant 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refrigerant spray (RS)
Study: 10726107
Drug: Postprandial lipemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial lipemia (200 ml of 30% cream) in IHD patients
Study: 10726107
Drug: Postprandial lipemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial lipemia (200 ml of 30% cream) in healthy controls
Study: 1786763
Drug: Accelerated hyperfractionation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionation with twice-a-day irradiation (Group B)
Study: 15592062
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tamsulosin once daily every day
Study: 15592062
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin once daily every other day
Study: 12095019
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg kg(‐1) plus fentanyl 1 microg kg(‐1))
Study: 7600031
Drug: Etoposide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (50 mg/m2/day) p.o. for 21 consecutive days and cisplatin (100 mg/m2) i.v. on day 1 every 28 days for up to six courses
Study: 7600031
Drug: Etoposide and
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide and cisplatin combination therapy
Study: 220889
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of naloxone
Study: 220889
Drug: Endorphin injections
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endorphin injections
Study: 16704584
Drug: Potassium permanganate
Normalized name: Potassium Permanganate
DrugBank: Potassium permanganate (DB13831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium permanganate 8 mg.l(‐1)
Study: 15035935
Drug: Mandatory drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory drug testing program (SATURN) for high school student athletes
Study: 9037645
Drug: Protocol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol group (oxygen delivery targeted towards 600 ml/min/m2)
Study: 8198908
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion for induction and maintenance (target concentration 8 micrograms ml-1)
Study: 8198908
Drug: Propofol bolus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol bolus (2.5-3.5 mg kg-1)
Study: 8198908
Drug: Thiopentone (4-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4-5 mg kg-1)
Study: 12686786
Drug: Nimodipine treatment
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine treatment
Study: 30488350
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) 800 mg/m2 bi-weekly and Temsirolimus (T) 10 mg weekly, escalated until dose-limiting toxicities (DLTs) were reached.
Study: 30488350
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) and Temsirolimus (T) combination treatment.
Study: 26104022
Drug: Triple plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple plus bismuth therapy
Study: 24124451
Drug: OPAL-HIV-Gag(c) 12
Normalized name: carbetapentane tannate / chlorpheniramine tannate Oral Suspension [C-Tanna 12]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPAL-HIV-Gag(c) 12 mg
Study: 24124451
Drug: OPAL-HIV-Gag(c) 24
Normalized name: C.i. solvent red 24
DrugBank: Scarlet red (DB19136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPAL-HIV-Gag(c) 24 mg
Study: 21918162
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of ropivacaine 1%, 3 mL before and after surgery
Study: 21918162
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of ropivacaine 0.5%, 20 mL after induction of the pneumoperitoneum
Study: 15269135
Drug: Aromasin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromasin (25 mg daily)
Study: 15269135
Drug: Femara (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femara (2.5 mg daily)
Study: 11359133
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL fibrin glue with 4% lidocaine chloride (group C)
Study: 11359133
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL fibrin glue using CaCl2 as solution to dissolve thrombin (group B)
Study: 9694028
Drug: D-fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-fenfluramine (30 mg)
Study: 8481358
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with medroxyprogesterone acetate (MPA) 100 mg t.i.d. p.o. from diagnosis for 90 days
Study: 2906343
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel (LNG)
Study: 2906343
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing ethinyl estradiol and gestodene (GTD)
Study: 16238558
Drug: Ring Block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ring Block (RB) with 1-1.5 ml
Study: 16238558
Drug: Dorsal Penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal Penile Block with 1.5-4 ml
Study: 16238558
Drug: Combined Ring
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Ring and Dorsal Penile Block with 2.5-5 ml
Study: 11991432
Drug: Contraceptive steroid
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive steroid treatment followed by estrogen replacement therapy
Study: 11991432
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estrogens and a progestin
Study: 11991432
Drug: No estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: No estrogen replacement therapy
Study: 7596116
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (100 mg)
Study: 7596116
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (100 mg) after salt depletion
Study: 2193713
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg flunarizine
Study: 2193713
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg flunarizine
Study: 23140261
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg single dose)
Study: 21856480
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (0.5 mg/kg per h)
Study: 21856480
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (various doses from 0.005 to 1.0 mg/kg per h)
Study: 19247541
Drug: Mitt use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitt use during therapy
Study: 19247541
Drug: No mitt
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mitt use during therapy
Study: 31888723
Drug: Metoprolol (95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (95 mg daily for 6 months)
Study: 26378681
Drug: Salsalate (2500-4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (2500-4500 mg for 4 days)
Study: 23694720
Drug: LY2140023 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 (40 mg BID)
Study: 9415330
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (diphenhydramine, Maalox, and local analgesic)
Study: 31944546
Drug: Higher starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher starting dose of insulin glargine 100 U/mL (0.3 U/kg)
Study: 31944546
Drug: Standard starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard starting dose of insulin glargine 100 U/mL (0.2 U/kg)
Study: 26537735
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation, 6 g daily (3.9 g n-3 PUFA) for 9 months
Study: 26537735
Drug: Maize oil
Normalized name: Maize oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize oil (MO) supplementation, 6 g daily for 9 months
Study: 7783313
Drug: TAZ/PIPC (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAZ/PIPC (2.5 g twice a day for 14 days)
Study: 7783313
Drug: PIPC (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPC (2.0 g twice a day for 14 days)
Study: 2128828
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with leuprolide and flutamide
Study: 319662
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 to 10 mg)
Study: 319662
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (10 to 30 mg)
Study: 319662
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (7.5 to 20 mg)
Study: 31250758
Drug: M2000 (mannuronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (mannuronic acid) 500mg orally twice per day for 12 weeks
Study: 28237542
Drug: Single-implant retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-implant retained overdentures
Study: 28237542
Drug: Two-implant retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant retained overdentures
Study: 20495936
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment during gestation
Study: 9373050
Drug: Isradipine (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5-5 mg, slow-release)
Study: 8207317
Drug: LMWH-Fluxum 3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH-Fluxum 3200 IUaXa daily (Group A)
Study: 8207317
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin 5000 IU three times daily (Group B)
Study: 26728864
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of alcoholic drinks at least weekly
Study: 18433425
Drug: yohimbine 16.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine 16.2 mg p.o. t.i.d. for 7 days
Study: 16154274
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (4-6mg dosed by ideal body weight)
Study: 16154274
Drug: Morphine minus
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine minus placebo analgesia calculation
Study: 14989112
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of inhaled corticosteroid (ICS) therapy
Study: 14989112
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) therapy continued
Study: 14989112
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of ICS therapy
Study: 6383927
Drug: Monotard MC
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotard MC + Actrapid MC (human insulin)
Study: 6383927
Drug: Monotard HM
Normalized name: DEXTRAN HM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotard HM + Actrapid HM (porcine insulin)
Study: 30052317
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a representative antiperspirant formulation containing 26 Al chlorohydrate (ACH)
Study: 22941746
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for UHR patients plus treatment as usual (CBTuhr)
Study: 19838862
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus (saffron) 30 mg/day (15 mg twice per day)
Study: 19838862
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day (5 mg twice per day)
Study: 18023680
Drug: Coronary artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary artery bypass grafting with intensive medical therapy
Study: 18023680
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and coronary artery bypass grafting
Study: 18023680
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and coronary artery bypass grafting with surgical ventricular reconstruction
Study: 12045679
Drug: NNRTI-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNRTI-containing triple therapy
Study: 12045679
Drug: 5-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-drug regimen
Study: 12045679
Drug: PI-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-containing triple therapy
Study: 12045679
Drug: Double NRTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double NRTI therapy
Study: 9528731
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg once daily for 12 weeks
Study: 9528731
Drug: Immediate-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release niacin 1 g three times daily for 12 weeks
Study: 2104939
Drug: Indomethacin (Indo)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (Indo) 100 mg IV 6 hours postoperatively and 3 x 50 mg IV Indo over 24 hours on postoperative days 1, 2, 3, 4
Study: 27591917
Drug: Defined symptom-change
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defined symptom-change trajectories (linear, log-linear, one-step) during acute-phase cognitive therapy
Study: 20594395
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g farmed trout raised on marine feed
Study: 20594395
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g farmed trout raised on vegetable feed
Study: 20594395
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g chicken
Study: 17321529
Drug: 400 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mug of oral misoprostol
Study: 17321529
Drug: 5 U
Normalized name: vitamin E 5 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 U of intravenous oxytocin
Study: 7737719
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral bromocriptine
Study: 2202544
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg daily)